Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 130.33 Billion JPY | 1.91% |
| 2023 | 127.88 Billion JPY | 3.86% |
| 2022 | 123.13 Billion JPY | 29.2% |
| 2021 | 95.3 Billion JPY | -10.27% |
| 2020 | 106.2 Billion JPY | 7.7% |
| 2019 | 98.61 Billion JPY | -2.27% |
| 2018 | 100.9 Billion JPY | 46.47% |
| 2017 | 68.89 Billion JPY | -27.78% |
| 2016 | 95.39 Billion JPY | 3.21% |
| 2015 | 92.42 Billion JPY | 85.23% |
| 2014 | 49.89 Billion JPY | 44.59% |
| 2013 | 34.5 Billion JPY | 1.67% |
| 2012 | 33.94 Billion JPY | 19.52% |
| 2011 | 28.39 Billion JPY | -3.0% |
| 2010 | 29.27 Billion JPY | 14.16% |
| 2009 | 25.64 Billion JPY | -12.86% |
| 2008 | 29.42 Billion JPY | -3.36% |
| 2007 | 30.45 Billion JPY | -4.3% |
| 2006 | 31.82 Billion JPY | 0.26% |
| 2005 | 31.74 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 116.3 Billion JPY | -9.05% |
| 2024 Q4 | 130.33 Billion JPY | 0.38% |
| 2024 FY | 130.33 Billion JPY | 1.91% |
| 2024 Q3 | 129.83 Billion JPY | 7.72% |
| 2024 Q2 | 120.53 Billion JPY | 3.63% |
| 2023 Q3 | 119.87 Billion JPY | 2.31% |
| 2023 Q2 | 117.16 Billion JPY | -1.02% |
| 2023 FY | 127.88 Billion JPY | 3.86% |
| 2023 Q4 | 127.88 Billion JPY | 6.68% |
| 2023 Q1 | 118.37 Billion JPY | -3.86% |
| 2022 Q3 | 108.82 Billion JPY | 7.31% |
| 2022 Q1 | 86.05 Billion JPY | -9.7% |
| 2022 Q2 | 101.4 Billion JPY | 17.84% |
| 2022 Q4 | 123.13 Billion JPY | 13.15% |
| 2022 FY | 123.13 Billion JPY | 29.2% |
| 2021 FY | 95.3 Billion JPY | -10.27% |
| 2021 Q1 | 103.76 Billion JPY | -2.3% |
| 2021 Q2 | 104.38 Billion JPY | 0.6% |
| 2021 Q3 | 98.35 Billion JPY | -5.78% |
| 2021 Q4 | 95.3 Billion JPY | -3.11% |
| 2020 Q3 | 103.89 Billion JPY | 1.98% |
| 2020 Q2 | 101.88 Billion JPY | 5.63% |
| 2020 FY | 106.2 Billion JPY | 7.7% |
| 2020 Q1 | 96.44 Billion JPY | -2.2% |
| 2020 Q4 | 106.2 Billion JPY | 2.22% |
| 2019 Q2 | 95.43 Billion JPY | 7.07% |
| 2019 Q4 | 98.61 Billion JPY | 10.16% |
| 2019 Q3 | 89.51 Billion JPY | -6.2% |
| 2019 FY | 98.61 Billion JPY | -2.27% |
| 2019 Q1 | 89.13 Billion JPY | -11.67% |
| 2018 Q2 | 102.38 Billion JPY | 57.65% |
| 2018 FY | 100.9 Billion JPY | 46.47% |
| 2018 Q4 | 100.9 Billion JPY | 3.86% |
| 2018 Q3 | 97.15 Billion JPY | -5.11% |
| 2018 Q1 | 64.94 Billion JPY | -5.74% |
| 2017 Q1 | 72.52 Billion JPY | -23.97% |
| 2017 FY | 68.89 Billion JPY | -27.78% |
| 2017 Q4 | 68.89 Billion JPY | 2.39% |
| 2017 Q3 | 67.28 Billion JPY | -1.76% |
| 2017 Q2 | 68.49 Billion JPY | -5.57% |
| 2016 Q2 | 101.18 Billion JPY | 19.11% |
| 2016 Q1 | 84.94 Billion JPY | -8.08% |
| 2016 FY | 95.39 Billion JPY | 3.21% |
| 2016 Q4 | 95.39 Billion JPY | -5.68% |
| 2016 Q3 | 101.13 Billion JPY | -0.05% |
| 2015 Q3 | 82.5 Billion JPY | 12.36% |
| 2015 Q4 | 92.42 Billion JPY | 12.02% |
| 2015 FY | 92.42 Billion JPY | 85.23% |
| 2015 Q1 | 75.73 Billion JPY | 51.79% |
| 2015 Q2 | 73.43 Billion JPY | -3.04% |
| 2014 FY | 49.89 Billion JPY | 44.59% |
| 2014 Q4 | 49.89 Billion JPY | 23.71% |
| 2014 Q3 | 40.33 Billion JPY | 0.42% |
| 2014 Q2 | 40.16 Billion JPY | 14.57% |
| 2014 Q1 | 35.05 Billion JPY | 1.59% |
| 2013 FY | 34.5 Billion JPY | 1.67% |
| 2013 Q4 | 34.5 Billion JPY | 24.56% |
| 2013 Q2 | 30.22 Billion JPY | 24.89% |
| 2013 Q3 | 27.7 Billion JPY | -8.34% |
| 2013 Q1 | 24.2 Billion JPY | -28.69% |
| 2012 Q4 | 33.94 Billion JPY | 31.59% |
| 2012 Q3 | 25.79 Billion JPY | -1.94% |
| 2012 Q2 | 26.3 Billion JPY | 10.32% |
| 2012 Q1 | 23.84 Billion JPY | -16.04% |
| 2012 FY | 33.94 Billion JPY | 19.52% |
| 2011 Q3 | 22.16 Billion JPY | -13.72% |
| 2011 FY | 28.39 Billion JPY | -3.0% |
| 2011 Q1 | 22.36 Billion JPY | -23.59% |
| 2011 Q2 | 25.68 Billion JPY | 14.83% |
| 2011 Q4 | 28.39 Billion JPY | 28.14% |
| 2010 Q3 | 25.69 Billion JPY | -11.79% |
| 2010 FY | 29.27 Billion JPY | 14.16% |
| 2010 Q2 | 29.12 Billion JPY | 0.0% |
| 2010 Q4 | 29.27 Billion JPY | 13.94% |
| 2009 Q4 | 25.64 Billion JPY | 0.0% |
| 2009 FY | 25.64 Billion JPY | -12.86% |
| 2008 FY | 29.42 Billion JPY | -3.36% |
| 2007 FY | 30.45 Billion JPY | -4.3% |
| 2006 FY | 31.82 Billion JPY | 0.26% |
| 2005 FY | 31.74 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | -110.667% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | -98.45% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -8364.012% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -192618.884% |
| Novartis AG | 53.19 Billion USD | -145.004% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -50821.991% |